Imane Bardan, Lene M Sundbakk, Joe Sexton, Tore K Kvien, Øyvind Molberg, Eirik K Kristianslund, Sella A Provan, Anna-Birgitte Aga
{"title":"Comorbidity and mortality in adults with juvenile idiopathic arthritis: a nationwide Norwegian register-based matched cohort study.","authors":"Imane Bardan, Lene M Sundbakk, Joe Sexton, Tore K Kvien, Øyvind Molberg, Eirik K Kristianslund, Sella A Provan, Anna-Birgitte Aga","doi":"10.1093/rheumatology/keag507","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This population-based study assesses comorbidities, autoimmune conditions and all-cause mortality in [1] adults with juvenile idiopathic arthritis (JIA) against general population comparators and [2] adults with JIA with vs without recent disease-modifying anti-rheumatic drug (DMARD) exposure.</p><p><strong>Methods: </strong>We included adults who, between 2009 and 2024, had ≥2 specialist health contacts with a JIA-specific ICD-10 code in the mandatory Norwegian Patient Registry (NPR). Each case was matched randomly, by age, gender and county of residence, to 10 general population comparators at the time of receiving the second JIA diagnosis in adulthood. We compared 5-year retrospective comorbidity prevalences in descriptive analyses and prospective all-cause mortality in [1] adults with JIA vs comparators and [2] adult JIA with vs without recent DMARD exposure.</p><p><strong>Results: </strong>Adults with JIA (N = 2932) had higher prevalence than comparators (N = 29 097) of ischemic heart disease excluding myocardial infarction [JIA vs comparators (%): 1.0 vs 0.6], hypertension (3.6 vs 1.4), chronic kidney disease (0.5 vs 0.2), type 1 diabetes (1.7 vs 0.7), coeliac disease (1.4 vs 0.7), autoimmune thyroiditis (0.3 vs 0.1) and autoimmune alopecia (0.4 vs 0.1). Prospective all-cause mortality was higher in JIA than comparators (mortality rate 2.4 vs 1.8 per 1000 person-years). In adult JIA, prevalences of comorbidities and autoimmune conditions as well as all-cause mortality was similar in those with and without recent DMARD exposure.</p><p><strong>Conclusion: </strong>In this study we found an increased 5-year retrospective prevalence of several comorbidities and increased all-cause mortality in adults with JIA compared with population controls.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633849/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keag507","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This population-based study assesses comorbidities, autoimmune conditions and all-cause mortality in [1] adults with juvenile idiopathic arthritis (JIA) against general population comparators and [2] adults with JIA with vs without recent disease-modifying anti-rheumatic drug (DMARD) exposure.
Methods: We included adults who, between 2009 and 2024, had ≥2 specialist health contacts with a JIA-specific ICD-10 code in the mandatory Norwegian Patient Registry (NPR). Each case was matched randomly, by age, gender and county of residence, to 10 general population comparators at the time of receiving the second JIA diagnosis in adulthood. We compared 5-year retrospective comorbidity prevalences in descriptive analyses and prospective all-cause mortality in [1] adults with JIA vs comparators and [2] adult JIA with vs without recent DMARD exposure.
Results: Adults with JIA (N = 2932) had higher prevalence than comparators (N = 29 097) of ischemic heart disease excluding myocardial infarction [JIA vs comparators (%): 1.0 vs 0.6], hypertension (3.6 vs 1.4), chronic kidney disease (0.5 vs 0.2), type 1 diabetes (1.7 vs 0.7), coeliac disease (1.4 vs 0.7), autoimmune thyroiditis (0.3 vs 0.1) and autoimmune alopecia (0.4 vs 0.1). Prospective all-cause mortality was higher in JIA than comparators (mortality rate 2.4 vs 1.8 per 1000 person-years). In adult JIA, prevalences of comorbidities and autoimmune conditions as well as all-cause mortality was similar in those with and without recent DMARD exposure.
Conclusion: In this study we found an increased 5-year retrospective prevalence of several comorbidities and increased all-cause mortality in adults with JIA compared with population controls.
目的:这项基于人群的研究评估了(1)青少年特发性关节炎(JIA)成人患者与一般人群比较者的合并症、自身免疫性疾病和全因死亡率;(2)JIA成人患者近期是否接触过改善疾病的抗风湿药物(DMARD)。方法:我们纳入了2009-2024年期间在强制性挪威患者登记处(NPR)中具有jia特定ICD-10代码的≥2次专家健康接触的成年人。每个病例在成年后接受第二次JIA诊断时,按年龄、性别和居住县随机匹配到10个一般人群比较者。我们比较了描述性分析中的5年回顾性合并症患病率和前瞻性全因死亡率:(1)JIA成人与比较组,(2)近期暴露于DMARD的JIA成人与未暴露于DMARD的JIA成人。结果:JIA成人(N = 2932)在不包括心肌梗死的缺血性心脏病(JIA与比较组(%):1.0 vs. 0.6)、高血压(3.6 vs. 1.4)、慢性肾病(0.5 vs. 0.2)、1型糖尿病(1.7 vs. 0.7)、乳糜泻(1.4 vs. 0.7)、自身免疫性甲状腺炎(0.3 vs. 0.1)和自身免疫性脱发(0.4 vs. 0.1)的患病率高于比较组(N = 29097)。JIA的前瞻性全因死亡率高于比较组(死亡率为每1000人年2.4 vs 1.8)。在成人JIA中,近期有或没有DMARD暴露者的合并症、自身免疫性疾病以及全因死亡率的患病率相似。结论:在这项研究中,我们发现与人群对照相比,JIA成人中几种合并症的5年回顾性患病率增加,全因死亡率增加。
期刊介绍:
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.